MiMedx Group, Inc. (MDXG) should be watched closely as summer turns into fall as the company's upcoming restated financials could be showing up in part or in whole at any time. Regaining compliance with up-to-date financials should result in a re-listing on the Nasdaq in short order presumably before the end of 2019. MiMedx is expected to host its 2019 Annual Meeting later this year to fully refresh its Board which could coincide around the time the company's financials are released. MiMedx's Phase 2 clinical study for osteoarthritis of the knee is scheduled